Literature DB >> 18831681

In vitro susceptibilities of aerobic and facultatively anaerobic gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2005 results from Study for Monitoring Antimicrobial Resistance Trends (SMART).

Fernando Baquero1, Po-Ren Hsueh, David L Paterson, Flávia Rossi, Grant V Bochicchio, Gale Gallagher, Keith Lantz, Javier Baez Villasenor, Kathleen McCarroll, Murray A Abramson, Joseph W Chow.   

Abstract

BACKGROUND: The Study for Monitoring Antimicrobial Resistance Trends (SMART) is examining aerobic and facultatively anaerobic gram-negative bacilli (GNB) isolated from intra-abdominal infections. This report summarizes the 2005 annual data.
METHODS: During 2005, 76 medical centers in 31 countries in five regions collected intra-abdominal GNB for antimicrobial susceptibility testing using broth microdilution according to the Clinical and Laboratory Standards Institute guidelines.
RESULTS: A total of 5,476 unique aerobic and facultatively anaerobic GNB were isolated. Enterobacteriaceae accounted for 86% (4,711) of the total isolates. Among the 12 antimicrobial agents tested, the carbapenems and amikacin were the most reliably active against the Enterobacteriaceae, whereas ampicillin/sulbactam most often was the least active. Escherichia coli was the species most commonly isolated, at 48% (2,654). Extended-spectrum beta-lactamases (ESBLs) were detected phenotypically in 12% (325/2,329) of E. coli and 18% (151/856) of Klebsiella spp. In general, ESBL producers demonstrated lower susceptibility to the majority of the antibiotics than the non-producers; however, ESBL producers usually were susceptible to the carbapenems tested.
CONCLUSIONS: In 2005, antibiotic resistance continued to be a problem among GNB isolated from intra-abdominal infections, with the highest resistance rates observed in the Asia/Pacific region. Imipenem-cilastatin, ertapenem, and amikacin were the agents most consistently active in vitro against the Enterobacteriaceae isolated.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18831681     DOI: 10.1089/sur.2008.0020

Source DB:  PubMed          Journal:  Surg Infect (Larchmt)        ISSN: 1096-2964            Impact factor:   2.150


  15 in total

1.  Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).

Authors:  Daryl J Hoban; Samuel K Bouchillon; Stephen P Hawser; Robert E Badal; Vincent J Labombardi; Joseph DiPersio
Journal:  Antimicrob Agents Chemother       Date:  2010-05-10       Impact factor: 5.191

2.  Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum beta-lactamases: a prospective study with Swedish volunteers.

Authors:  Thomas Tängdén; Otto Cars; Asa Melhus; Elisabeth Löwdin
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

Review 3.  Preventing surgical site infections after bariatric surgery: value of perioperative antibiotic regimens.

Authors:  Teena Chopra; Jing J Zhao; George Alangaden; Michael H Wood; Keith S Kaye
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2010-06       Impact factor: 2.217

4.  Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrobial Resistance Trends (SMART).

Authors:  Stephen P Hawser; Samuel K Bouchillon; Daryl J Hoban; Robert E Badal; Rafael Cantón; Fernando Baquero
Journal:  Antimicrob Agents Chemother       Date:  2010-04-26       Impact factor: 5.191

5.  Clinical characteristics of bloodstream infections due to ampicillin-sulbactam-resistant, non-extended- spectrum-beta-lactamase-producing Escherichia coli and the role of TEM-1 hyperproduction.

Authors:  Rebecca I Waltner-Toews; David L Paterson; Zubair A Qureshi; Hanna E Sidjabat; Jennifer M Adams-Haduch; Kathleen A Shutt; Mark Jones; Guo-Bao Tian; Anthony W Pasculle; Yohei Doi
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

6.  Cephalosporin MIC distribution of extended-spectrum-{beta}-lactamase- and pAmpC-producing Escherichia coli and Klebsiella species.

Authors:  Peggy C Kohner; Frans J L Robberts; Franklin R Cockerill; Robin Patel
Journal:  J Clin Microbiol       Date:  2009-06-03       Impact factor: 5.948

7.  In vitro activities of moxifloxacin and tigecycline against bacterial isolates associated with intraabdominal infections at a medical center in Taiwan, 2001-2006.

Authors:  C-Y Liu; C-L Lu; Y-T Huang; C-H Liao; P-R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-09-08       Impact factor: 3.267

Review 8.  Extended Antibiotic Prophylaxis May Be Linked to Lower Peri-prosthetic Joint Infection Rates in High-Risk Patients: An Evidence-Based Review.

Authors:  Christopher J DeFrancesco; Michael C Fu; Cynthia A Kahlenberg; Andy O Miller; Mathias P Bostrom
Journal:  HSS J       Date:  2019-06-19

9.  Depolymerase improves gentamicin efficacy during Klebsiella pneumoniae induced murine infection.

Authors:  Shruti Bansal; Kusum Harjai; Sanjay Chhibber
Journal:  BMC Infect Dis       Date:  2014-08-23       Impact factor: 3.090

Review 10.  Resistant gram-negative infections in the outpatient setting in Latin America.

Authors:  M J C Salles; J Zurita; C Mejía; M V Villegas
Journal:  Epidemiol Infect       Date:  2013-08-07       Impact factor: 2.451

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.